The Ohio State University Corporate Engagement Office

Back to All Technologies

Thermogenic Biologicals Treatment of Obesity and Improvement of Insulin Resistance

Healthcare Portfolios
Life Sciences
Drug Delivery
Therapeutics
College
College of Education & Human Ecology
Researchers
Ziouzenkova, Ouliana
Parquette, Jonathan
Licensing Manager
Flammang, Ann Marie
614-292-9839
flammang.2@osu.edu

TS-037746 — Innovative thermogenic biologicals, methods of delivery, and combinational therapy for the treatment of abdominal obesity

Obesity as a result of an increase in intra-abdominal (or visceral) fat is an independent risk factor for major diseases such as type 2 diabetes and cardiovascular diseases due to increases in insulin resistance and chronic inflammation. Accumulation of intra-abdominal fat, even in non-­obese …

The Need

Obesity as a result of an increase in intra-abdominal (or visceral) fat is an independent risk factor for major diseases such as type 2 diabetes and cardiovascular diseases due to increases in insulin resistance and chronic inflammation. Accumulation of intra-abdominal fat, even in non-­obese people, is strongly associated with all-cause mortality in people under 65 years of age. Obesity is notoriously difficult to treat as a psycho-somatic disorder, which depends on lifestyle, endocrine, environmental, and genetic factors affecting basal metabolism in patients. Reduction of abdominal fat improves health outcomes, but is extremely difficult to achieve. Targeted therapies that address not only the fat accumulation, but also the neurological pathways that regulate dietary intake and hormonal status are needed to reduce obesity. One avenue of exploration has been thermogenesis, however, to date, there are no specific therapies derived from this that target intra-abdominal obesity. Regulation of local thermogenesis in intra-abdominal fat tissues provide a feasible approach to reduce obesity and improve insulin resistance.

The Technology

Researchers at The Ohio State University, led by Dr. Jonathan Parquette and Dr. Ouliana Ziouzenkova identified innovative thermogenic and neurologic biologicals for use as combinational therapy with novel nanostructure, nanotubes and nanofibers) for the treatment of diabetes and intra-abdominal obesity. The combinational therapy are capable of an improvement of glucose metabolism, increasing metabolic rate and mitochondrial oxidation, but reducing cholesterol synthesis gene expression. The efficacy of biologicals was achieved due to the ability nanostructures to stabilize proteins, deliver compounds to specific tissue, and provide microenvironments for signaling without release, and due to specific metabolic effects of nanostructure .

Commercial Applications

  • Biomedical treatments directed at targeting:
    • intra-abdominal obesity
    • Type 2 diabetes
    • Cancer suppression
  • Obesity research

Benefits/Advantages

  • Tissue specific treatment that limits side effects
  • Decreases deleterious intra-abdominal fat without affecting insulin-sensitizing subcutaneous depot
  • Nanotubes offer a strategy for tissue-specific delivery and protein stabilization to a spectrum of other biologicals